Novo Nordisk: Patients Switching From Obesity Injections to Oral Wegovy Kept Losing Weight

The significance lies less in the weight-loss numbers than in the delivery format: an oral option that holds or extends results could loosen the injection's grip on the category and reshape how long patients stay on therapy. The caveat is built into the data itself — association, not causation — so the finding is suggestive rather than settled. The question worth tracking is whether this real-world signal holds up in broader and longer use, and whether it shifts the competitive ground between oral and injectable obesity treatments.